C.R. Reddy Cancer Center · Leela Mahal Road, Nellore
Dr. Haritha ChiramanaMD, DMSenior medical oncologist & hemato-oncologistNellore Patient guides Book a Consultation
For health professionals. This section uses clinical terms and is general education for doctors, nurses and students, not advice for an individual patient. Patients and families: please read our patient guides instead, Cancer Myth Busters · Understanding your cancer report · Living through cancer treatment, or speak with your own doctor.
← Sarcoma mini review

Sarcoma: MCQ bank

102 clinical-vignette questions in three levels: 34 basics, 34 applied and innovative, and 34 challenging (58 Soft tissue, 30 Bone, 14 Metastatic; 7 built on schematic imaging, endoscopy or histology drawings). Practise question by question with instant marking, or take a timed mock test with a result summary by topic, level and section. You can also print the page as a booklet.

LevelScore 0 / 0 answered
Topic

Level 1 · Basics

Core facts for NEET-PG and USMLE Step 1–2: histology, risk factors, presentation, staging and first-line principles.

Q1Soft tissueLevel 1At a glance

Which statement about the relative frequency of sarcomas is correct?

  1. ASoft tissue sarcomas outnumber bone sarcomas by roughly four to one
  2. BOsteosarcoma is the commonest sarcoma in older adults
  3. CSoft tissue and bone sarcomas are about equally common
  4. DSarcomas account for about 10% of adult cancers
  5. EBone sarcomas outnumber soft tissue sarcomas by roughly four to one
Show answer

Answer: A. There are more than 100 subtypes, and soft tissue sarcoma is about four times commoner than bone sarcoma. Sarcomas are only about 1% of adult cancers but roughly 1 in 7 to 1 in 10 childhood and adolescent cancers.

Review: section 01

Q2Soft tissueLevel 1At a glance

Which three types are the commonest soft tissue sarcomas in adults?

  1. ARhabdomyosarcoma, synovial sarcoma and Ewing sarcoma
  2. BAngiosarcoma, Kaposi sarcoma and MPNST
  3. CAlveolar soft part, clear cell and epithelioid sarcoma
  4. DDesmoid tumour, GIST and dermatofibrosarcoma protuberans
  5. EUndifferentiated pleomorphic sarcoma, liposarcoma and leiomyosarcoma
Show answer

Answer: E. UPS, liposarcoma and leiomyosarcoma lead in adults. Rhabdomyosarcoma and Ewing sarcoma are mainly tumours of children and young adults, and the others are uncommon. GIST and desmoid are separate diseases.

Review: section 01

Q3BoneLevel 1At a glance

A 15-year-old boy has had knee pain for 3 months that now wakes him at night, with a firm swelling above the knee. Which tumour is most likely?

  1. AConventional chondrosarcoma
  2. BOsteochondroma
  3. COsteosarcoma of the distal femur
  4. DSynovial sarcoma of the knee joint
  5. EChronic osteomyelitis
Show answer

Answer: C. Osteosarcoma peaks in teenagers and arises in the metaphysis around the knee. Conventional chondrosarcoma is a tumour of adults over 40. Night pain in a teenager is not growing pains.

Review: section 01

Q4BoneLevel 1ImagePresentation, traps & genetics

This schematic radiograph is from a 15-year-old with night pain above the knee. Which finding points to osteosarcoma?

Rdistal femur, APSchematic drawing · not a patient image
  1. AMultiple well-defined lucent lesions in the epiphysis
  2. BA uniformly sclerotic bone with no soft tissue mass
  3. CA calcified cartilage cap on a bony stalk
  4. DA sunburst periosteal reaction with a Codman triangle in the metaphysis
  5. EOnion-skin layering of the diaphysis
Show answer

Answer: D. Bone-forming osteosarcoma gives a mixed lytic and sclerotic metaphyseal lesion with sunburst spicules and a Codman triangle. Onion-skin layering with a permeative diaphyseal pattern suggests Ewing sarcoma, and a cartilage cap suggests an osteochondroma or chondrosarcoma.

Review: section 02

Q5BoneLevel 1Presentation, traps & genetics

Where is Ewing sarcoma most characteristically found?

  1. AIn the epiphysis of the proximal tibia in older adults
  2. BIn the metaphysis of the distal femur in teenagers only
  3. CIn the diaphysis of a long bone, the pelvis or the ribs, in children and young adults
  4. DIn the phalanges of the hand in middle age
  5. EIn the skull vault in adults over 60
Show answer

Answer: C. Ewing sarcoma arises in long-bone diaphyses, the pelvis and the ribs, and can also arise in soft tissue. It affects children and young adults.

Review: section 02

Q6BoneLevel 1At a glance

Which statement about conventional chondrosarcoma is correct?

  1. AIt mostly affects children under 10 and responds well to chemotherapy
  2. BIt mainly affects adults over 40 and is chemoresistant, so surgery is the only effective treatment
  3. CIt is treated with the same chemotherapy as osteosarcoma
  4. DIt is radiosensitive and is managed with radiotherapy alone
  5. EIt never occurs in the pelvis
Show answer

Answer: B. Conventional chondrosarcoma occurs in adults (pelvis, femur, shoulder girdle) and does not respond to chemotherapy. Surgery is the treatment; dedifferentiated and mesenchymal variants are handled differently.

Review: section 01

Q7Soft tissueLevel 1Presentation, traps & genetics

A 45-year-old has a painless, slowly enlarging 7 cm lump deep in the thigh. What is the most appropriate next step?

  1. AObservation for 3 months
  2. BFNAC alone, with reassurance if it is benign
  3. CUltrasound only, and discharge if there is no pain
  4. DMRI of the thigh with contrast before any biopsy or excision
  5. EExcision biopsy under local anaesthesia
Show answer

Answer: D. A lump that is large (over 5 cm), deep or growing needs MRI before a knife. Pain does not separate benign from malignant soft tissue masses; size, depth and growth do.

Review: section 02

Q8Soft tissueLevel 1Presentation, traps & genetics

Which feature most raises the suspicion that a soft tissue lump is a sarcoma?

  1. AA history of a single minor injury
  2. BPain only at night
  3. CA soft consistency
  4. DTenderness on palpation
  5. ESize over 5 cm, depth below the fascia, or growth
Show answer

Answer: E. Size, depth and growth are the clues. Pain is uncommon until the tumour is large, and an injury often only draws attention to a tumour that was already present.

Review: section 02

Q9Soft tissueLevel 1Screening, workup & staging

Which biopsy approach is preferred for a suspected limb sarcoma?

  1. AFrozen section during a planned excision elsewhere
  2. BExcision of the whole lump as the biopsy
  3. CA transverse incisional biopsy
  4. DImage-guided core needle biopsy after MRI, along a track that will be removed with the tumour
  5. EFNAC alone
Show answer

Answer: D. Core biopsy with several cores, planned with the surgeon, is the default. FNAC alone is inaccurate for subtype and grade, and a transverse cut contaminates more tissue and enlarges the resection.

Review: section 03

Q10Soft tissueLevel 1Screening, workup & staging

Which grading system is used for soft tissue sarcomas?

  1. AWHO CNS grading
  2. BNottingham (Bloom–Richardson)
  3. CFuhrman
  4. DGleason
  5. EFNCLCC (differentiation, mitotic count and necrosis)
Show answer

Answer: E. FNCLCC grade is built from differentiation, mitoses and necrosis, and predicts metastasis in most subtypes.

Review: section 03

Q11Soft tissueLevel 1Screening, workup & staging

Which investigation should every adult with a new soft tissue sarcoma have to look for metastases?

  1. ACT of the chest
  2. BMRI of the brain
  3. CSerum LDH
  4. DChest radiograph only
  5. EBone scan
Show answer

Answer: A. The lung holds about 80% of metastases, so CT chest is standard. A chest radiograph is acceptable only for small low-grade tumours, and brain MRI is kept for particular subtypes.

Review: section 03

Q12Soft tissueLevel 1Biomarkers

Which fusion characterises synovial sarcoma?

  1. AEWSR1::FLI1
  2. BCOL1A1::PDGFB
  3. CFUS::DDIT3
  4. DPAX3::FOXO1
  5. ESS18::SSX1/2/4
Show answer

Answer: E. SS18::SSX is the diagnostic fusion of synovial sarcoma. EWSR1::FLI1 is Ewing sarcoma, FUS::DDIT3 myxoid liposarcoma, PAX3::FOXO1 alveolar rhabdomyosarcoma and COL1A1::PDGFB dermatofibrosarcoma protuberans.

Review: section 04

Q13Soft tissueLevel 1Biomarkers

MDM2 amplification on FISH helps to distinguish which pair?

  1. AGIST from desmoid tumour
  2. BSynovial sarcoma from Ewing sarcoma
  3. COsteosarcoma from osteomyelitis
  4. DLeiomyosarcoma from leiomyoma
  5. EWell-differentiated liposarcoma from lipoma
Show answer

Answer: E. MDM2 amplification separates atypical lipomatous tumour or well-differentiated liposarcoma from lipoma, and dedifferentiated liposarcoma from UPS. Any retroperitoneal “UPS” should be tested.

Review: section 04

Q14Soft tissueLevel 1Presentation, traps & genetics

A 28-year-old woman has an osteosarcoma. Her mother had breast cancer at 36 and her brother had an adrenocortical tumour in childhood. Which germline gene should be tested?

  1. AVHL
  2. BTP53
  3. CAPC
  4. DMLH1
  5. ENF2
Show answer

Answer: B. This pattern suggests Li-Fraumeni syndrome (germline TP53): sarcoma at a young age with family cancers. Radiotherapy is avoided where possible in carriers.

Review: section 02

Q15Soft tissueLevel 1Presentation, traps & genetics

A patient with neurofibromatosis type 1 has a plexiform neurofibroma that has recently become painful and hard. What is the concern and the next step?

  1. ANormal growth of a neurofibroma; reassure
  2. BA lipoma; excise locally
  3. CA schwannoma; observe
  4. DA desmoid tumour; start imatinib
  5. EMalignant peripheral nerve sheath tumour; MRI with or without PET, then biopsy
Show answer

Answer: E. MPNST has a lifetime risk of about 8–13% in NF1. Pain, growth or hardening of a plexiform neurofibroma needs MRI, often PET, and biopsy.

Review: section 02

Q16Soft tissueLevel 1Presentation, traps & genetics

What is the usual latency of a radiation-associated sarcoma?

  1. AAbout 1–2 years
  2. BUnder 6 months
  3. CUsually 7–16 years, shorter (4–8 years) for angiosarcoma after breast radiotherapy
  4. DAlways over 40 years
  5. EThere is no latency; they appear during radiotherapy
Show answer

Answer: C. The absolute risk is low (well under 1%) but persists for decades. The criteria are a sarcoma in a previously irradiated field, a different histology from the first cancer, and a latency of at least 3 years (classically over 5).

Review: section 02

Q17Soft tissueLevel 1Presentation, traps & genetics

A long-standing swollen arm after mastectomy and axillary surgery develops purple nodules. Which diagnosis must be excluded by biopsy?

  1. ALymphangiosarcoma (Stewart–Treves syndrome)
  2. BLipoedema
  3. CVenous ulceration
  4. DContact dermatitis
  5. ERecurrent cellulitis
Show answer

Answer: A. Purple nodules or bruise-like patches on a chronically lymphoedematous limb need a punch biopsy for angiosarcoma (Stewart–Treves).

Review: section 02

Q18Soft tissueLevel 1Local therapy

What did the NCI trial by Rosenberg (1982) show?

  1. ARadiotherapy alone was as good as surgery
  2. BAmputation gave better survival than limb salvage
  3. CLimb-sparing surgery with radiotherapy gave the same survival as amputation
  4. DPreoperative radiotherapy reduced distant metastases
  5. EAdjuvant chemotherapy cured most patients
Show answer

Answer: C. Limb salvage with radiotherapy became standard, and amputation is now needed in under 5–10% of patients.

Review: section 05

Q19Soft tissueLevel 1Local therapy

A “lipoma” is excised in a minor theatre and histology shows a high-grade sarcoma with involved margins. What should be done next?

  1. AMRI of the site and re-excision of the scar and tumour bed, after expert pathology review
  2. BNo further local treatment, because the lump has been removed
  3. CReassure and review in 3 months
  4. DPostoperative chemotherapy alone
  5. EWait for a local recurrence
Show answer

Answer: A. Residual tumour is found in about half of unplanned excisions (Noria 1996). Re-image with MRI, review the pathology and re-excise the scar and bed; radiotherapy can secure control where re-excision would cost function.

Review: section 05

Q20Soft tissueLevel 1Local therapy

What is the standard preoperative radiotherapy dose for a soft tissue sarcoma of the limb?

  1. A50 Gy in 25 fractions
  2. B66 Gy in 33 fractions
  3. C20 Gy in 5 fractions
  4. D30 Gy in 10 fractions
  5. E75 Gy in 30 fractions
Show answer

Answer: A. Preoperative RT is 50 Gy in 25 fractions with surgery 4–6 weeks later. Postoperative doses are 60 Gy for a negative margin, 66 Gy for a positive margin and up to 75 Gy for gross residual disease. Shorter schedules remain investigational.

Review: section 05

Q21Soft tissueLevel 1Local therapy

Compared with postoperative radiotherapy, preoperative radiotherapy for limb sarcoma causes:

  1. AWorse local control
  2. BWorse overall survival
  3. CMore late fibrosis and joint stiffness
  4. DNo wound complications
  5. EMore wound complications but less permanent late fibrosis
Show answer

Answer: E. In NCIC SR2 local control and survival were equal, wound complications were 35% versus 17%, and late fibrosis was lower with preoperative RT, which is why it is preferred for most patients.

Review: section 05

Q22Soft tissueLevel 1At a glance

Which statement about retroperitoneal sarcoma is correct?

  1. AIt is usually under 3 cm at diagnosis
  2. BIt is cured by biopsy and radiotherapy alone
  3. CIt nearly always presents with early jaundice
  4. DIt commonly spreads to lymph nodes
  5. EIt is often silent until large, about 15 cm at diagnosis
Show answer

Answer: E. Retroperitoneal sarcoma (10–15% of soft tissue sarcomas) produces fullness, early satiety or leg symptoms late. Nodal spread is uncommon, and complete resection at the first operation is the only cure.

Review: section 01

Q23BoneLevel 1Systemic therapy

What does MAP stand for in osteosarcoma chemotherapy?

  1. AMelphalan, doxorubicin and carboplatin
  2. BMesna, ifosfamide and pazopanib
  3. CMethotrexate, actinomycin and procarbazine
  4. DMitomycin, ifosfamide and paclitaxel
  5. EHigh-dose methotrexate, doxorubicin (Adriamycin) and cisplatin
Show answer

Answer: E. MAP is standard up to age 40: about 10 weeks before surgery, resumed a week after surgery to complete about 29 weeks.

Review: section 06

Q24BoneLevel 1Systemic therapy

Which regimen is the backbone of Ewing sarcoma chemotherapy?

  1. AMAP
  2. BVDC/IE (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide)
  3. CDoxorubicin plus trabectedin
  4. DGemcitabine plus docetaxel
  5. EWeekly paclitaxel
Show answer

Answer: B. Adding ifosfamide and etoposide to VDC improved 5-year event-free survival in localised disease (INT-0091). Adults receive the same protocol at full intensity.

Review: section 06

Q25BoneLevel 1Systemic therapy

Which factor is the strongest prognostic marker after metastatic status in osteosarcoma?

  1. AHistological necrosis in the resection specimen after preoperative chemotherapy (90% or more is a good response)
  2. BHow much the mass shrinks on X-ray
  3. CPD-L1 expression
  4. DSerum CEA
  5. EThe patient’s height
Show answer

Answer: A. Response is judged on the resection specimen, not on how much the mass shrinks.

Review: section 06

Q26MetastaticLevel 1Systemic therapy

What is the reference first-line drug for most patients with metastatic soft tissue sarcoma?

  1. AGemcitabine alone
  2. BDoxorubicin
  3. CPazopanib
  4. DCisplatin
  5. EImatinib
Show answer

Answer: B. Doxorubicin remains the reference first line. Combinations raise response rates but not clearly survival (EORTC 62012).

Review: section 06

Q27Soft tissueLevel 1Systemic therapy

Which drug requires an echocardiogram before treatment and a record of the lifetime cumulative dose?

  1. ADoxorubicin
  2. BEribulin
  3. CTrabectedin
  4. DMethotrexate
  5. EPazopanib
Show answer

Answer: A. Doxorubicin causes cumulative cardiomyopathy, so echo or MUGA beforehand and tracking of the lifetime dose are needed, with precautions against extravasation.

Review: section 06

Q28Soft tissueLevel 1Systemic therapy

Which measure prevents ifosfamide haemorrhagic cystitis?

  1. ADexrazoxane
  2. BMesna with hydration
  3. CLeucovorin
  4. DAllopurinol
  5. EAmifostine
Show answer

Answer: B. Ifosfamide also causes encephalopathy and a proximal tubulopathy (Fanconi syndrome), so kidney function, phosphate and bicarbonate are monitored. Leucovorin is the rescue for methotrexate.

Review: section 06

Q29MetastaticLevel 1Systemic therapy

In advanced soft tissue sarcoma, pazopanib is not used for which group?

  1. AMPNST
  2. BSynovial sarcoma
  3. CLeiomyosarcoma
  4. DAdipocytic sarcomas (liposarcoma)
  5. EUndifferentiated pleomorphic sarcoma
Show answer

Answer: D. Pazopanib (PALETTE: PFS 4.6 versus 1.6 months, no overall survival gain) is for non-adipocytic sarcomas. Eribulin is the later-line drug with a survival benefit in liposarcoma.

Review: section 06

Q30Soft tissueLevel 1Systemic therapy

Which drug is the usual first line for cutaneous angiosarcoma of the scalp and face?

  1. ATazemetostat
  2. BHigh-dose methotrexate
  3. CImatinib
  4. DWeekly paclitaxel
  5. EPazopanib
Show answer

Answer: D. Weekly paclitaxel is the first choice (ANGIOTAX). Checkpoint inhibitors are particularly active in cutaneous head and neck angiosarcoma.

Review: section 06

Q31Soft tissueLevel 1Survivorship

When do most relapses of soft tissue sarcoma occur?

  1. ARelapse is rare after complete resection
  2. BIn the first 2–3 years, so surveillance is front-loaded
  3. COnly in the first month
  4. DEvenly across 10 years
  5. EAfter 15 years
Show answer

Answer: B. Examination and chest CT are most frequent in the first 2–3 years, to catch lung metastases and local relapse while they can be resected. Retroperitoneal liposarcoma is the exception and recurs late.

Review: section 08

Q32BoneLevel 1Survivorship

Before cisplatin, ifosfamide or other alkylating chemotherapy in a 15-year-old boy, which step is often forgotten?

  1. AThyroid screening
  2. BA live vaccine
  3. CSperm banking
  4. DDental extraction
  5. EBone marrow harvest
Show answer

Answer: C. Fertility preservation (sperm banking, or ovarian protection) must be arranged before starting treatment, and it is often forgotten in the rush to begin.

Review: section 08

Q33BoneLevel 1Screening, workup & staging

Which investigation should come first in a teenager with persistent bone pain?

  1. ASerum calcium only
  2. BBone biopsy at the local hospital
  3. CA plain X-ray of the whole bone in two planes
  4. DA bone density scan
  5. EA trial of antituberculous treatment
Show answer

Answer: C. The plain X-ray is still the first and most useful bone test. MRI of the whole bone follows, and the patient should be referred before any biopsy.

Review: section 03

Q34Soft tissueLevel 1Presentation, traps & genetics

Which statement about lymph node metastasis in sarcoma is correct?

  1. ANodes are involved in most soft tissue sarcomas
  2. BNodal spread is the commonest route of metastasis
  3. CNodal disease never occurs in sarcoma
  4. DSentinel node biopsy is routine in all sarcomas
  5. ENodal involvement is uncommon (under 5%) except in clear cell, epithelioid, angiosarcoma and rhabdomyosarcoma
Show answer

Answer: E. Lymph nodes are rarely involved, so routine node dissection or sentinel biopsy is not used. In the subtypes named, examine the regional nodal basin; nodal spread then makes a limb or trunk sarcoma stage IV.

Review: section 02

Level 2 · Applied & innovative

Clinical reasoning: calculations (pack-years, predicted lung function, NNT), CT and fluid findings, reading trial results, sequencing traps.

Q35Soft tissueLevel 2Local therapy

A 52-year-old man had an 8 cm “lipoma” of the thigh excised under local anaesthesia, with a drain brought out 10 cm away. Histology: high-grade pleomorphic sarcoma with involved margins. Which plan is most appropriate?

  1. AAdjuvant chemotherapy alone
  2. BMRI of the thigh and CT chest, expert pathology review, preoperative RT that includes the scar and drain track, then re-excision
  3. CHip disarticulation
  4. DObservation with MRI at 6 months
  5. ERe-excise only the scar, without radiotherapy
Show answer

Answer: B. The scar and drain site are contaminated and must be treated; an unplanned excision enlarges both the radiotherapy field and the definitive operation. For stage III UPS, pembrolizumab with RT can be discussed (SU2C-SARC032).

Review: section 05

Q36Soft tissueLevel 2Systemic therapy

In SU2C-SARC032 (stage III limb UPS or pleomorphic or dedifferentiated liposarcoma), adding pembrolizumab to preoperative RT and surgery:

  1. AHad no effect on disease-free survival
  2. BImproved 2-year disease-free survival (67 vs 52%) with more grade 3 or worse toxicity (56 vs 31%); overall survival is not yet known
  3. CWas tested together with doxorubicin–ifosfamide chemotherapy
  4. DImproved overall survival by 20% with no extra toxicity
  5. EReplaced the need for surgery
Show answer

Answer: B. It is the first immunotherapy result in localised sarcoma. Offer it after shared decision-making where access allows; survival data are immature and it was not tested with chemotherapy.

Review: section 06

Q37Soft tissueLevel 2Local therapy

Which patient with a limb soft tissue sarcoma can reasonably be treated with wide excision alone?

  1. AA deep 9 cm grade 3 tumour
  2. BAny tumour next to a nerve
  3. CA tumour with a positive margin that cannot be re-excised
  4. DAn 8 cm myxofibrosarcoma with infiltrative margins
  5. EA superficial 4 cm grade 1 tumour with clear margins
Show answer

Answer: E. Surgery alone is reasonable for superficial, ≤5 cm, low-grade tumours with clear margins (Yang 1998). Radiotherapy adds local control, but not survival, for most tumours that are over 5 cm or deep, and grade 2–3.

Review: section 05

Q38Soft tissueLevel 2Local therapy

After preoperative RT, a thigh sarcoma is resected with a 2 mm margin where it abuts an intact fascial plane, and the sciatic nerve is preserved. How is this margin regarded?

  1. AUnacceptable unless a 5 cm margin is achieved
  2. BOften adequate: fascia, periosteum and vessel adventitia are good barriers, and planned close margins beside a preserved nerve or vessel are acceptable after preoperative RT
  3. CAlways an R2 resection
  4. DAn indication for amputation
  5. EImpossible to judge without a PET scan
Show answer

Answer: B. An adequate margin is not a single number. About 1 cm of fat or muscle, or an intact fascial plane, is usually enough with radiotherapy.

Review: section 05

Q39Soft tissueLevel 2Local therapy

What target volume was used for preoperative RT in RTOG 0630?

  1. AThe tumour only, with no margin
  2. BThe tumour plus 10 cm in every direction
  3. CThe regional lymph node basin
  4. DThe tumour plus about 1.5 cm radially and 3–4 cm along the muscle, including T2 oedema where feasible
  5. EThe whole limb
Show answer

Answer: D. Image-guided preoperative RT to these reduced volumes gave few marginal failures and late grade 2 or worse toxicity of about 10%, showing that smaller margins are safe.

Review: section 05

Q40Soft tissueLevel 2ImageScreening, workup & staging

A 34-year-old man has this deep posterior thigh mass (schematic T2 MRI). Core biopsy: myxoid liposarcoma with a FUS::DDIT3 fusion. Which staging is specific to this subtype?

T2 axialdeep posterior massSchematic drawing · not a patient image
  1. APET-CT alone
  2. BBone marrow aspirate only
  3. CCT chest only
  4. DCT chest, CT abdomen-pelvis and whole-spine MRI; PET may miss disease
  5. EMRI of the brain
Show answer

Answer: D. Myxoid liposarcoma spreads to soft tissue, the retroperitoneum and bone marrow without lung disease, so the spine and abdomen are imaged. It is exceptionally radiosensitive and trabectedin is active.

Review: section 03

Q41Soft tissueLevel 2Local therapy

In the DOREMY phase 2 trial of preoperative RT for myxoid liposarcoma, 36 Gy gave:

  1. AA higher amputation rate
  2. BWorse local control than surgery alone
  3. CNo pathological response
  4. D91% extensive pathological response and no local failures
  5. EResults proven equal to 50 Gy in a phase 3 trial
Show answer

Answer: D. It supports dose de-escalation in an exceptionally radiosensitive tumour, but 50 Gy remains the standard outside trials.

Review: section 05

Q42Soft tissueLevel 2ImageScreening, workup & staging

A 58-year-old woman has abdominal fullness. This schematic CT shows a large fatty left retroperitoneal mass with thick septa and a solid enhancing nodule. What does the nodule suggest, and what is the best next step?

kidneyfatty masssolid noduleRSchematic drawing · not a patient image
  1. AA benign lipoma; observe
  2. BA germ cell tumour; orchidectomy
  3. CLymphoma; excision biopsy at laparotomy
  4. DRenal angiomyolipoma; embolise
  5. EDedifferentiation within a well-differentiated liposarcoma; percutaneous posterior core biopsy of the nodule and discussion at a sarcoma MDT
Show answer

Answer: E. Fat with a solid non-fatty nodule indicates dedifferentiation. Percutaneous posterior core biopsy of a retroperitoneal mass is safe and does not raise local recurrence; open or laparoscopic biopsy is avoided.

Review: section 03

Q43Soft tissueLevel 2Local therapy

How should the result of STRASS be applied to retroperitoneal sarcoma?

  1. APreoperative RT is standard for every retroperitoneal sarcoma
  2. BPreoperative RT did not improve abdominal recurrence-free survival overall; it is an option in selected well-differentiated and low-grade dedifferentiated liposarcoma after MDT discussion
  3. CRadiotherapy should never be used
  4. DChemotherapy replaces surgery
  5. EPostoperative RT is preferred
Show answer

Answer: B. Postoperative RT is avoided because bowel falls into the tumour bed. Surgery by an experienced team remains the key treatment.

Review: section 05

Q44Soft tissueLevel 2Local therapy

At the first operation for a resectable retroperitoneal liposarcoma, which approach gives the best local control?

  1. ACompartmental en bloc resection including adherent organs, by an experienced team
  2. BEnucleation along the capsule
  3. CLaparoscopic morcellation
  4. DDebulking with planned reoperation
  5. EOpen biopsy followed by chemotherapy
Show answer

Answer: A. Extended resection improves local control in liposarcoma (Bonvalot 2009). Never enucleate, morcellate or “debulk” at the first operation, and refer before laparotomy.

Review: section 05

Q45Soft tissueLevel 2Screening, workup & staging

A 47-year-old woman had a hysterectomy for a rapidly growing “fibroid” that proved to be leiomyosarcoma, and now has a cough. Which staging is most appropriate?

  1. ABone scan only
  2. BMRI of the brain
  3. CChest X-ray only
  4. DNo imaging, because the uterus has been removed
  5. ECT of the chest and abdomen including the liver
Show answer

Answer: E. Leiomyosarcoma metastasises to lung and liver, so both are scanned. Power morcellation of a fibroid with suspicious features should be avoided because it can spread an unsuspected sarcoma.

Review: section 03

Q46Soft tissueLevel 2ImagePresentation, traps & genetics

A 64-year-old woman treated with breast-conserving surgery and RT 7 years ago has had this violaceous, bruise-like patch for 2 months and was given antibiotics for “cellulitis”. What is the next step?

old lumpectomy scarSchematic drawing · not a patient image
  1. ATopical steroids
  2. BA longer course of antibiotics
  3. CObservation for 6 months
  4. DMultiple punch biopsies from the darkest areas
  5. EMammography alone and reassurance
Show answer

Answer: D. A bruise that will not fade on an irradiated breast is angiosarcoma until a punch biopsy says otherwise; reassess any “bruise” persisting beyond 2 weeks. MYC amplification supports radiation-associated angiosarcoma.

Review: section 02

Q47Soft tissueLevel 2Local therapy

Biopsy confirms radiation-associated angiosarcoma of the breast. Which statement about local treatment is correct?

  1. AChemotherapy replaces surgery for localised disease
  2. BImatinib is first line
  3. CRadical resection of all irradiated skin where possible, with reconstruction, is the main treatment; the disease is often wider than imaging suggests
  4. DRadiotherapy alone is curative
  5. EWide local excision with a 1 cm margin is sufficient
Show answer

Answer: C. The disease is skin-led and multifocal. Re-irradiation (often hyperfractionated) and taxanes are used in selected cases.

Review: section 05

Q48Soft tissueLevel 2Local therapy

After breast-conserving therapy the 10-year incidence of sarcoma is about 0.16% (Wiener 2023). What follows from this?

  1. AIt is not a reason to withhold breast radiotherapy when it is indicated
  2. BRadiotherapy should be avoided in all breast cancer
  3. CAngiosarcoma is unrelated to radiotherapy
  4. DEvery survivor needs yearly breast skin MRI
  5. ESarcoma is commoner than breast cancer recurrence
Show answer

Answer: A. The absolute risk is very low and the benefit of radiotherapy in breast cancer is large. Persistent skin changes should still be biopsied.

Review: section 05

Q49BoneLevel 2Screening, workup & staging

A 15-year-old’s X-ray shows a sunburst lesion of the distal femur. Which sequence is correct?

  1. AImmediate biopsy at the nearest hospital, then referral
  2. BMRI of the whole femur, CT chest and PET-CT or bone scan, then core biopsy at the centre that will operate
  3. CChemotherapy before any tissue diagnosis
  4. DAmputation without biopsy
  5. ECurettage as for a suspected infection
Show answer

Answer: B. A poorly placed biopsy track can turn limb salvage into amputation, so plan the biopsy with the treating team. The whole bone is imaged for skip lesions, and baseline audiometry, echo and kidney function precede chemotherapy.

Review: section 03

Q50BoneLevel 2ImagePresentation, traps & genetics

A 24-year-old man has 4 months of thigh pain, fever and a raised ESR, and antituberculous treatment was started for a “lytic lesion” without a biopsy. His radiograph (schematic) shows a permeative, moth-eaten pattern with onion-skin layering and a soft tissue mass. What should be done?

Lfemoral diaphysis, APSchematic drawing · not a patient image
  1. ASix weeks of antibiotics without a biopsy
  2. BCT-guided core biopsy sent for histology, molecular testing and culture, and stop the unproven antituberculous treatment
  3. CCurettage and cementing
  4. DBone scan only
  5. EContinue antituberculous drugs for 6 months
Show answer

Answer: B. Fever, raised ESR and a bone lesion can be Ewing sarcoma. Send tissue for histology and culture together, and never curette a suspected sarcoma as if it were infection.

Review: section 02

Q51BoneLevel 2Systemic therapy

A 52-year-old has a high-grade osteosarcoma. Which chemotherapy is usual?

  1. APazopanib
  2. BVDC/IE
  3. CNo chemotherapy, because adults do not benefit
  4. DMAP exactly as for a teenager
  5. EDoxorubicin–cisplatin; the benefit of high-dose methotrexate is unproven at this age
Show answer

Answer: E. MAP is standard up to age 40. Where methotrexate cannot be monitored safely, carboplatin–ifosfamide–doxorubicin is an alternative, with more second leukaemias.

Review: section 06

Q52BoneLevel 2Systemic therapy

A teenager’s osteosarcoma shows 60% necrosis after preoperative MAP. What should the postoperative chemotherapy be?

  1. AAdd ifosfamide–etoposide, which improved survival
  2. BSwitch to VDC/IE
  3. CContinue MAP to complete about 29 weeks; changing or intensifying treatment did not help in EURAMOS-1
  4. DStop chemotherapy
  5. EAdd zoledronate to improve survival
Show answer

Answer: C. Adding ifosfamide–etoposide added toxicity only. Zoledronate (OS2006) and interferon maintenance for good responders (EURAMOS-1) were also negative.

Review: section 06

Q53BoneLevel 2Systemic therapy

Which is the correct overall sequence for localised Ewing sarcoma in a 17-year-old?

  1. AVDC/IE only after surgery
  2. BVDC/IE every 14 days for 12 weeks, local control (surgery or RT), then chemotherapy to a total of 14–17 cycles
  3. CSurgery first, then 6 cycles of MAP
  4. DInterferon maintenance after 4 cycles
  5. ERadiotherapy alone
Show answer

Answer: B. If radiotherapy is the local treatment, chemotherapy continues during it with doxorubicin omitted. From age 18, cycles may be given every 14 or 21 days.

Review: section 06

Q54BoneLevel 2Systemic therapy

What did AEWS0031 show?

  1. AAdding interferon improved survival
  2. BCycles every 14 days added toxicity with no benefit
  3. CVDC/IE every 14 days instead of 21 improved 10-year event-free survival (70 vs 61%) without more toxicity
  4. DAdding vincristine–topotecan–cyclophosphamide improved survival
  5. EA higher dose per cycle improved survival
Show answer

Answer: C. Interval compression with growth-factor support is the benefit. Higher doses per cycle (Granowetter 2009) and adding vincristine–topotecan–cyclophosphamide (AEWS1031) did not help.

Review: section 06

Q55BoneLevel 2Local therapy

A Ewing sarcoma of the iliac wing with a large mass is judged unresectable without mutilation. Which local treatment is appropriate?

  1. ARadiotherapy after 3 years
  2. BDefinitive RT (about 55 Gy) with chemotherapy continuing, omitting doxorubicin during RT
  3. CHemipelvectomy regardless of function
  4. DNo local treatment; chemotherapy alone
  5. EIntralesional curettage
Show answer

Answer: B. Definitive RT is used when the tumour is unresectable or resection would be mutilating (spine, much of the pelvis, skull base). Postoperative RT is given for positive margins, gross residual disease or high-risk chest wall tumours.

Review: section 05

Q56MetastaticLevel 2Systemic therapy

A fit 47-year-old woman has metastatic uterine leiomyosarcoma (lung and liver). Which first-line regimen improved both PFS and overall survival in a randomised trial?

  1. AGemcitabine–docetaxel
  2. BDoxorubicin plus trabectedin, followed by trabectedin maintenance (LMS-04)
  3. CPazopanib alone
  4. DImatinib
  5. EObservation
Show answer

Answer: B. PFS was 12 versus 6 months and overall survival 33 versus 24 months, but grade 3 or worse toxicity was 97%, so growth-factor support and LFT and CK monitoring are needed. Doxorubicin plus dacarbazine is an alternative.

Review: section 06

Q57MetastaticLevel 2Systemic therapy

In EORTC 62012, adding ifosfamide to doxorubicin in first-line metastatic soft tissue sarcoma:

  1. ADoubled the response rate (26 vs 14%) and lengthened PFS without a significant survival gain
  2. BReduced toxicity
  3. CWas inferior in every subtype
  4. DHad no effect on response
  5. EImproved overall survival significantly
Show answer

Answer: A. Use the combination when shrinkage is the goal (symptoms, borderline resectable disease); otherwise single-agent doxorubicin is reasonable.

Review: section 06

Q58MetastaticLevel 2Systemic therapy

A 68-year-old has metastatic dedifferentiated liposarcoma and wants symptom control with the least toxicity. What is the first line?

  1. ADoxorubicin plus ifosfamide at once
  2. BPazopanib
  3. CImatinib
  4. DTrabectedin alone in every case
  5. ESingle-agent doxorubicin; combinations only when a response is needed
Show answer

Answer: E. Doxorubicin alone is reasonable when palliation is the aim. Pazopanib is not used for adipocytic sarcomas.

Review: section 06

Q59MetastaticLevel 2Systemic therapy

A patient with advanced PEComa should receive:

  1. AAn mTOR inhibitor (nab-sirolimus; sirolimus or everolimus where it is unavailable)
  2. BCisplatin
  3. CDoxorubicin plus ifosfamide
  4. DWeekly paclitaxel
  5. EImatinib
Show answer

Answer: A. PEComa shows TSC1/2 loss and chemotherapy has little activity. Watch for hyperglycaemia, stomatitis and pneumonitis.

Review: section 06

Q60MetastaticLevel 2Biomarkers

A young adult with an advanced sarcoma has an NTRK fusion found by RNA sequencing. Which treatment gives high, durable responses?

  1. APazopanib
  2. BMifamurtide
  3. CImatinib
  4. DLarotrectinib or entrectinib
  5. EAtezolizumab
Show answer

Answer: D. TRK inhibitors give high, durable responses in any tumour type. Screen with pan-TRK IHC and confirm with RNA NGS; NTRK fusions are rare in adult sarcoma but common in infantile fibrosarcoma.

Review: section 04

Q61MetastaticLevel 2ImageLocal therapy

Three years after treatment of a grade 3 synovial sarcoma near the knee, a 29-year-old woman has two new right-lung nodules on surveillance CT (schematic), with nothing elsewhere on PET-CT. What is the best approach?

Rlung window, axialSchematic drawing · not a patient image
  1. AAdjuvant MAP after resection
  2. BObserve until symptoms develop
  3. CWhole-lung radiotherapy
  4. DRepeat CT at 6–8 weeks to test the tempo, then VATS resection if no new lesions, with no routine adjuvant chemotherapy
  5. EStart palliative chemotherapy at once
Show answer

Answer: D. Selection explains much of the benefit: long disease-free interval, few nodules, controlled primary and no extrathoracic disease. Five-year survival after resection is about 30–40% in series.

Review: section 05

Q62BoneLevel 2Systemic therapy

Which medicines should be avoided during high-dose methotrexate for osteosarcoma, and what is used for severely delayed clearance?

  1. AAvoid NSAIDs, PPIs and co-trimoxazole; glucarpidase for delayed clearance
  2. BAvoid allopurinol; give hydroxocobalamin
  3. CAvoid statins; give dexrazoxane
  4. DAvoid mesna; give amifostine
  5. EAvoid antiemetics; give rasburicase
Show answer

Answer: A. Hydration, urine alkalinisation, drug levels and leucovorin rescue are routine. NSAIDs, PPIs and co-trimoxazole delay clearance, and glucarpidase is used for delayed clearance.

Review: section 06

Q63BoneLevel 2Survivorship

Which long-term effects should be anticipated after cisplatin and ifosfamide for a bone sarcoma?

  1. APulmonary fibrosis and hypothyroidism only
  2. BCardiomyopathy from cisplatin
  3. CHair depigmentation
  4. DPeripheral neuropathy only from ifosfamide
  5. EHearing loss and renal tubular loss of phosphate and magnesium
Show answer

Answer: E. Audiometry and magnesium monitoring are needed with cisplatin, and kidney tubular damage follows ifosfamide and cisplatin. Anthracyclines cause cardiomyopathy and alkylators cause infertility and second cancers.

Review: section 08

Q64Soft tissueLevel 2Survivorship

For how long should retroperitoneal liposarcoma be followed with imaging?

  1. AFor 6 months
  2. BOnly if symptoms develop
  3. CFor 2 years
  4. DBeyond 10 years, because liposarcoma recurs late and can dedifferentiate
  5. EUntil the first scan is clear
Show answer

Answer: D. CT abdomen-pelvis and chest is done every 3–6 months for 2–3 years, then every 6–12 months. Leiomyosarcoma, by contrast, metastasises early.

Review: section 08

Q65Soft tissueLevel 2Survivorship

Which imaging is preferred to follow the primary site after limb sarcoma resection with positive margins or at a hard-to-examine site?

  1. ANo imaging
  2. BPET-CT every 3 months
  3. CUltrasound every 3 months only
  4. DMRI about 6-monthly for 2 years, then yearly to 5 years
  5. EChest radiograph yearly
Show answer

Answer: D. MRI is preferred to CT for the primary site (better sensitivity, no radiation). Chest CT surveillance for lung metastases continues alongside.

Review: section 08

Q66BoneLevel 2Survivorship

Which statement about late effects after treatment of a bone sarcoma in a young person is correct?

  1. ASurvivors cannot play sport
  2. BAn echocardiogram is needed only at diagnosis
  3. CAnthracycline cardiomyopathy, cisplatin hearing loss, infertility and second cancers can appear years later and need survivorship follow-up
  4. DLate effects do not occur after chemotherapy
  5. EOnly radiotherapy causes late effects
Show answer

Answer: C. Many young survivors walk, run and play sport. Late effects also include kidney damage, radiotherapy fibrosis, fracture and growth disturbance.

Review: section 08

Q67Soft tissueLevel 2Biomarkers

Which statement about GIST and desmoid tumour is correct?

  1. AGIST responds to MAP
  2. BBoth are bone tumours
  3. CDesmoid tumour is always treated by amputation
  4. DThey are separate diseases, not treated like soft tissue sarcoma: imatinib for GIST, and initial observation for desmoid
  5. EBoth are treated with doxorubicin–ifosfamide
Show answer

Answer: D. GIST is driven by KIT or PDGFRA (DOG1 positive); desmoid has nuclear β-catenin with CTNNB1 or APC changes and is observed first.

Review: section 04

Q68BoneLevel 2Systemic therapy

Why is preoperative chemotherapy preferred in osteosarcoma?

  1. AIt gives better survival than postoperative chemotherapy
  2. BIt prevents all metastases
  3. CIt allows radiotherapy to be omitted
  4. DIt eases limb salvage and allows necrosis to be assessed; survival is similar to postoperative timing
  5. EIt removes the need for surgery
Show answer

Answer: D. Preoperative and postoperative timing give similar survival, but preoperative treatment makes limb-sparing surgery easier and shows the histological response.

Review: section 06

Level 3 · Challenging

DNB, DM and USMLE Step 3 level: landmark trials, newer targeted drugs and difficult decisions.

Q69BoneLevel 3Systemic therapy

What did the Multi-Institutional Osteosarcoma Study (MIOS) establish?

  1. AAdjuvant chemotherapy after surgery raised relapse-free survival from about 17% to about 65%
  2. BInterferon maintenance prolonged survival
  3. CLimb salvage was inferior to amputation
  4. DRadiotherapy can replace surgery
  5. EZoledronate improved survival
Show answer

Answer: A. Chemotherapy before and after surgery raised long-term survival of localised osteosarcoma from under 20% to about 65–70%, making chemotherapy standard.

Review: section 06

Q70BoneLevel 3Systemic therapy

In INT-0091, adding ifosfamide and etoposide to VDC in localised Ewing sarcoma gave 5-year event-free survival of:

  1. A45% versus 44%
  2. B30% versus 20%
  3. C54% versus 69%
  4. D69% versus 54%
  5. E90% versus 70%
Show answer

Answer: D. This established VDC/IE as the backbone of Ewing sarcoma chemotherapy.

Review: section 06

Q71BoneLevel 3Systemic therapy

In Euro Ewing 2012, VDC/IE compared with VIDE gave:

  1. A3-year EFS 67 vs 61% and overall survival 82 vs 74%, with less febrile neutropenia
  2. BMore toxicity with VDC/IE
  3. CWorse survival with VDC/IE
  4. DBetter results only in adults
  5. ENo difference in any outcome
Show answer

Answer: A. This made VDC/IE the single international standard.

Review: section 06

Q72Soft tissueLevel 3Systemic therapy

How should the pooled evidence for adjuvant doxorubicin–ifosfamide (Pervaiz 2008, EORTC 62931) be applied?

  1. AGive it to every patient with soft tissue sarcoma
  2. BGive it only to patients over 70
  3. CGive it to all low-grade tumours
  4. DNever give it
  5. EOffer chemotherapy only to fit patients with high-risk tumours (over 5 cm, deep, grade 2–3, ideally chemosensitive types) after shared decision-making
Show answer

Answer: E. The meta-analysis suggested an 11% absolute survival gain, but the largest trial was negative, partly because it included small, low-grade and non-limb tumours. Benefit is modest and uncertain.

Review: section 06

Q73Soft tissueLevel 3Systemic therapy

ISG-STS 1001 compared three cycles of epirubicin plus ifosfamide with histotype-tailored regimens in high-risk soft tissue sarcoma. What was the conclusion?

  1. AFive cycles were superior to three
  2. BThe standard regimen was better overall; high-grade myxoid liposarcoma, where the tailored drug is trabectedin, was the exception
  3. CThe trial was negative for toxicity only
  4. DTailored regimens were superior in every histotype
  5. EBoth arms had identical results in every histotype
Show answer

Answer: B. Three cycles were also as effective as five in the earlier trial (Gronchi 2016), so three cycles is the regimen used when chemotherapy is given.

Review: section 06

Q74MetastaticLevel 3Systemic therapy

Which statement about first-line trials in metastatic soft tissue sarcoma is correct?

  1. AGemcitabine–docetaxel was superior to doxorubicin
  2. BGemcitabine–docetaxel was not better than doxorubicin and was more toxic (GeDDiS); olaratumab’s phase 2 signal was not confirmed in phase 3
  3. COlaratumab doubled survival in phase 3
  4. DPazopanib beat doxorubicin first line
  5. ETrabectedin beat doxorubicin in every subtype
Show answer

Answer: B. Olaratumab is a lesson in confirming phase 2 signals with a phase 3 trial (Tap 2016).

Review: section 06

Q75MetastaticLevel 3Biomarkers

Which soft tissue sarcomas respond best to PD-1 blockade, and is PD-L1 a useful selector?

  1. AAll sarcomas equally; only PD-L1-high tumours respond
  2. BLeiomyosarcoma and synovial sarcoma; PD-L1 is the selector
  3. COsteosarcoma only
  4. DUPS, dedifferentiated liposarcoma, alveolar soft part sarcoma and cutaneous angiosarcoma; PD-L1 is not a useful selector
  5. EEwing sarcoma only
Show answer

Answer: D. Responses were seen mainly in those four types (SARC028, Alliance A091401), irrespective of PD-L1.

Review: section 04

Q76Soft tissueLevel 3Biomarkers

A 22-year-old woman has alveolar soft part sarcoma (ASPSCR1::TFE3) of the thigh with lung metastases. Which statement is correct?

  1. AImatinib is standard
  2. BChemotherapy is effective and curative
  3. CDoxorubicin is highly effective and should start at once
  4. DIt is indolent: limited stable disease can be observed, atezolizumab or pembrolizumab is used if it progresses, and brain MRI is part of staging
  5. EIt never metastasises to the brain
Show answer

Answer: D. Chemotherapy is ineffective. Pembrolizumab plus axitinib is used if the disease is bulky or symptomatic (Wilky 2019); pazopanib or sunitinib are later options.

Review: section 04

Q77Soft tissueLevel 3Biomarkers

Which pair is correct for epithelioid sarcoma?

  1. ANR4A3 fusion and middle-aged men
  2. BSMARCB1 (INI1) loss and nodal spread, with tazemetostat where approved
  3. CASPSCR1::TFE3 and brain metastases
  4. DEWSR1::ATF1 and BRAF V600E
  5. EWWTR1::CAMTA1 and liver involvement
Show answer

Answer: B. Epithelioid sarcoma affects young adults, mimics a granuloma or ulcer, and spreads to lymph nodes; anthracycline first if unresectable.

Review: section 04

Q78Soft tissueLevel 3Biomarkers

A tumour of the ankle tendons in a young adult is S100 and HMB45 positive but BRAF wild-type, with EWSR1::ATF1. Which is correct?

  1. AClear cell sarcoma: melanoma-like but distinct; nodal spread occurs and chemotherapy rarely works, so trials are preferred
  2. BChordoma: observe
  3. CMetastatic melanoma: treat with BRAF inhibitors
  4. DEpithelioid sarcoma: treat with tazemetostat
  5. ESynovial sarcoma: treat with ifosfamide
Show answer

Answer: A. EWSR1::ATF1 defines clear cell sarcoma, which is not a melanoma despite the immunophenotype.

Review: section 04

Q79Soft tissueLevel 3Biomarkers

Which tumour is indolent, occurs in middle-aged men in the thigh and carries an NR4A3 fusion?

  1. AExtraskeletal myxoid chondrosarcoma
  2. BDesmoplastic small round cell tumour
  3. CInflammatory myofibroblastic tumour
  4. DEpithelioid haemangioendothelioma
  5. EDedifferentiated liposarcoma
Show answer

Answer: A. Resect the primary and observe limited metastases; VEGFR tyrosine kinase inhibitors (sunitinib, pazopanib) are used if it progresses.

Review: section 04

Q80Soft tissueLevel 3Biomarkers

Which fusion is characteristic of epithelioid haemangioendothelioma, a slow, often multifocal tumour of liver, lung and bone?

  1. ANAB2::STAT6
  2. BSS18::SSX2
  3. CWWTR1::CAMTA1
  4. DEWSR1::WT1
  5. EETV6::NTRK3
Show answer

Answer: C. Surveillance comes first; systemic therapy is reserved for progression or symptoms.

Review: section 04

Q81Soft tissueLevel 3Systemic therapy

An ALK-positive inflammatory myofibroblastic tumour of the abdomen in a young adult is unresectable. Which drug class is used?

  1. ALarotrectinib
  2. BPazopanib
  3. CAn ALK inhibitor such as crizotinib
  4. DDoxorubicin–ifosfamide first
  5. EImatinib
Show answer

Answer: C. ALK fusions occur in about half of cases, and resection is the first choice when feasible.

Review: section 06

Q82Soft tissueLevel 3Systemic therapy

An adolescent boy has multiple peritoneal masses; biopsy shows small round blue cells with EWSR1::WT1. Which treatment approach is used?

  1. AMAP
  2. BEwing-type chemotherapy with debulking surgery and whole-abdomen RT in selected patients; the prognosis is poor
  3. CNab-sirolimus
  4. DObservation
  5. EImatinib
Show answer

Answer: B. This is a desmoplastic small round cell tumour of adolescents and young men.

Review: section 06

Q83Soft tissueLevel 3ImageBiomarkers

This schematic H&E field from a pelvic mass in a 19-year-old shows sheets of uniform small round blue cells. Which is the most useful next step?

Schematic drawing · not a patient image
  1. AGleason grading
  2. BS100 immunohistochemistry alone
  3. COestrogen receptor testing
  4. DCD99 and NKX2.2 immunohistochemistry with FISH or RNA-based fusion testing, on fresh or frozen tissue
  5. ESerum CEA
Show answer

Answer: D. Small round cell sarcomas need molecular confirmation. Ewing sarcoma carries EWSR1::FLI1 (about 85%) or EWSR1::ERG (about 10%); CIC::DUX4 and BCOR::CCNB3 sarcomas are separate, more aggressive entities.

Review: section 04

Q84BoneLevel 3Biomarkers

Which statement about the fusion type in Ewing sarcoma is correct?

  1. AFusion testing is unnecessary
  2. BThe fusion type decides between MAP and VDC/IE
  3. CEWSR1::FLI1 (about 85%) and EWSR1::ERG (about 10%) carry the same prognosis with modern therapy
  4. DCIC::DUX4 sarcomas are Ewing sarcoma with identical outcomes
  5. EEWSR1::ERG has a much worse prognosis
Show answer

Answer: C. Le Deley 2010 found that fusion type does not change prognosis, but molecular testing is still needed to confirm the diagnosis.

Review: section 04

Q85Soft tissueLevel 3Systemic therapy

Which are the eligibility requirements for afamitresgene autoleucel in synovial sarcoma, and what is its status in India?

  1. AHLA-A*02 and MAGE-A4 positivity; not yet available in India, so relevant for trial referral
  2. BNTRK fusion; available in India
  3. CPD-L1 positivity; widely available
  4. DMDM2 amplification; available
  5. EBRAF V600E; available
Show answer

Answer: A. SPEARHEAD-1 studied engineered T cells in synovial sarcoma and myxoid/round cell liposarcoma. Cytokine release syndrome and cytopenias are managed in a cell-therapy centre.

Review: section 06

Q86MetastaticLevel 3Systemic therapy

Which later-line option is used for indolent dedifferentiated liposarcoma because of CDK4 amplification?

  1. AImatinib
  2. BPazopanib
  3. CLarotrectinib
  4. DA CDK4/6 inhibitor (Dickson 2016)
  5. ETazemetostat
Show answer

Answer: D. MDM2 and CDK4 amplification mark well-differentiated and dedifferentiated liposarcoma. Pazopanib is not used in adipocytic sarcoma.

Review: section 06

Q87MetastaticLevel 3Systemic therapy

In which subtype did eribulin show an overall survival gain in a phase 3 trial (Schöffski 2016)?

  1. ALiposarcoma
  2. BSynovial sarcoma
  3. CAngiosarcoma
  4. DOsteosarcoma
  5. ELeiomyosarcoma
Show answer

Answer: A. This is why “pazopanib is not for liposarcoma; eribulin is.”

Review: section 06

Q88BoneLevel 3Biomarkers

What is the role of IDH1/2 mutation in conventional chondrosarcoma?

  1. ADiagnostic support in most conventional central tumours; IDH inhibitors are being tested in trials
  2. BIt selects patients for imatinib
  3. CIt is absent in chondrosarcoma
  4. DIt predicts response to MAP
  5. EIt mandates amputation
Show answer

Answer: A. IDH1/2 mutations are found in most conventional central chondrosarcomas, but there is no established IDH-directed therapy outside trials.

Review: section 04

Q89BoneLevel 3Systemic therapy

Which chemotherapy approach is used for dedifferentiated and for mesenchymal chondrosarcoma?

  1. AImatinib for both
  2. BGemcitabine–docetaxel for both
  3. CEwing-type for dedifferentiated, osteosarcoma-type for mesenchymal
  4. DNone for either
  5. EOsteosarcoma-type chemotherapy for dedifferentiated, Ewing-type for mesenchymal
Show answer

Answer: E. Conventional chondrosarcoma is chemoresistant, but these two variants are treated by analogy with their chemosensitive counterparts.

Review: section 06

Q90Soft tissueLevel 3Screening, workup & staging

What does the Sarculator nomogram provide, and what level of risk marks “high risk” for a perioperative chemotherapy discussion?

  1. ALocal recurrence only; 5%
  2. BA PD-L1 score; 10%
  3. CAn individual risk estimate for extremity soft tissue sarcoma that adds age, subtype and site to size and grade; a 10-year metastasis risk of about 40% or more
  4. DResponse to MAP; 90%
  5. ESurgical margin width; 1 mm
Show answer

Answer: C. Sarculator (Callegaro 2016) is used for extremity sarcoma; a histology-specific nomogram exists for the retroperitoneum (Gronchi 2013).

Review: section 03

Q91Soft tissueLevel 3Screening, workup & staging

What is known about tract seeding after a core needle biopsy of a sarcoma?

  1. AIt occurs only after FNAC
  2. BIt is rare (TARPSWG 2021), and percutaneous posterior core biopsy of a retroperitoneal sarcoma does not raise local recurrence
  3. CIt is a reason to prefer open biopsy
  4. DIt occurs in most patients
  5. EIt is common and a reason to avoid biopsy
Show answer

Answer: B. The biopsy track should still be placed where it will be removed with the tumour.

Review: section 03

Q92Soft tissueLevel 3Local therapy

What is the status of moderately hypofractionated (15 fractions) or 5-fraction preoperative RT for soft tissue sarcoma?

  1. AContraindicated
  2. BAn established standard that replaces 50 Gy in 25 fractions
  3. CPromising control with acceptable wound complication rates, but still investigational (HYPORT-STS, Kalbasi 2020)
  4. DReserved for brachytherapy
  5. EProven inferior
Show answer

Answer: C. Standard preoperative RT remains 50 Gy in 25 fractions outside trials.

Review: section 05

Q93Soft tissueLevel 3Local therapy

The NCI (Yang 1998) and MSKCC (Pisters 1996) trials of RT after limb-sparing surgery showed:

  1. ANo change in local control
  2. BBetter overall survival
  3. CBetter local control without a survival difference
  4. DFewer distant metastases
  5. EHigher amputation rates
Show answer

Answer: C. This is why radiotherapy is used for most large, deep, high-grade tumours, to protect the limb rather than to extend life.

Review: section 05

Q94BoneLevel 3Systemic therapy

Which statement about added agents in osteosarcoma is correct?

  1. AZoledronate added nothing (OS2006) and interferon maintenance was negative (EURAMOS-1); mifamurtide is used where licensed but is not available in India
  2. BMifamurtide is widely available in India
  3. CIfosfamide–etoposide improved outcomes for poor responders
  4. DZoledronate improved survival
  5. EInterferon improved survival for good responders
Show answer

Answer: A. Mifamurtide with MAP was studied in INT-0133 and is used where licensed.

Review: section 06

Q95BoneLevel 3Systemic therapy

Which statement about relapsed bone sarcoma is correct?

  1. ARadiotherapy alone is standard
  2. BRelapse is never curable
  3. COnly chemotherapy is used
  4. DResect lung metastases where possible; relapse over a year later with a few resectable nodules can still be cured by surgery; options include irinotecan–temozolomide or topotecan–cyclophosphamide in Ewing sarcoma and multitarget TKIs in osteosarcoma
  5. EImatinib is standard
Show answer

Answer: D. Trials are preferred. Osteosarcoma TKI evidence comes from REGOBONE and CABONE.

Review: section 06

Q96BoneLevel 3Systemic therapy

Which statement about metastatic Ewing sarcoma is correct?

  1. AWhole-lung RT is contraindicated
  2. BMetastatic Ewing sarcoma is always cured
  3. CBone marrow involvement carries the best outlook
  4. DSurgery alone is standard
  5. ELung-only disease has a better outlook (whole-lung RT after chemotherapy); bone or marrow metastases fare poorly
Show answer

Answer: E. High-dose busulfan–melphalan is used in some protocols for metastatic disease.

Review: section 06

Q97BoneLevel 3Systemic therapy

Which osteosarcoma subtypes usually need surgery alone?

  1. ARadiation-associated osteosarcoma
  2. BHigh-grade osteosarcoma of the jaw
  3. CLow-grade central and parosteal osteosarcoma
  4. DConventional high-grade osteosarcoma
  5. EOsteosarcoma in Paget disease
Show answer

Answer: C. Periosteal osteosarcoma is intermediate and chemotherapy is debated. High-grade tumours, including those of the jaw, usually get cisplatin-based chemotherapy.

Review: section 06

Q98Soft tissueLevel 3Local therapy

In childhood rhabdomyosarcoma of a parameningeal head and neck site, the standard treatment is:

  1. APazopanib
  2. BRadical surgery alone
  3. CChemotherapy with radiotherapy rather than radical surgery
  4. DObservation
  5. EWide local excision only
Show answer

Answer: C. 35–40% of childhood rhabdomyosarcomas arise in the head and neck, and paediatric-type sarcomas always receive protocol chemotherapy.

Review: section 05

Q99Soft tissueLevel 3Biomarkers

MYC amplification is used to:

  1. ADiagnose myxoid liposarcoma
  2. BConfirm Ewing sarcoma
  3. CSeparate post-radiation angiosarcoma from an atypical vascular lesion
  4. DSelect patients for larotrectinib
  5. EChoose pazopanib
Show answer

Answer: C. MYC amplification supports radiation-associated angiosarcoma over a benign post-radiation atypical vascular lesion.

Review: section 04

Q100MetastaticLevel 3Systemic therapy

Which monitoring is needed during pazopanib therapy?

  1. AAudiometry
  2. BWeekly CK
  3. CLiver tests at 3, 5, 7 and 9 weeks then monthly, blood pressure, and caution with many lung metastases (pneumothorax)
  4. DEchocardiogram every cycle only
  5. EDaily INR
Show answer

Answer: C. ALT above 3 times the upper limit of normal means interrupting the drug.

Review: section 06

Q101MetastaticLevel 3Systemic therapy

Which monitoring is specific to trabectedin?

  1. ATSH and cortisol
  2. BEchocardiogram and lifetime dose
  3. CAudiometry
  4. DUrine for blood with mesna
  5. ELFTs and CK every cycle, a central line, and dexamethasone premedication
Show answer

Answer: E. Trabectedin causes transaminitis, neutropenia and rhabdomyolysis; a rising CK or bilirubin means delaying or reducing the dose.

Review: section 06

Q102Soft tissueLevel 3Screening, workup & staging

A myxoid liposarcoma of the thigh has been staged with PET-CT only, which was negative. What is the problem?

  1. ANo problem: PET-CT is the best test for this subtype
  2. BPET misses myxoid liposarcoma; CT chest, CT abdomen-pelvis and whole-spine MRI are needed
  3. CIt needs no staging because it is radiosensitive
  4. DIt needs bone scan only
  5. EIt needs brain MRI
Show answer

Answer: B. This subtype spreads to extrapulmonary soft tissue, retroperitoneum and bone marrow.

Review: section 03

Prepared and reviewed by Dr. Haritha Chiramana for teaching. Facts compiled from current guidelines, primary trials and evidence summaries, written in our own words; drawings are original schematics, not patient images; no doses are included.